Scynexis (SCYX) Cash & Equivalents Growth (3y) (2016 - 2026)
Scynexis (SCYX) Cash & Equivalents Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 32.82% |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - | -8.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.20% |
| Mar 31, 2026 | 10.86% |
| Dec 31, 2025 | -22.58% |
| Sep 30, 2025 | -17.95% |
| Jun 30, 2025 | -54.72% |
| Mar 31, 2025 | -17.33% |
| Dec 31, 2024 | -46.44% |
| Sep 30, 2024 | -34.04% |
| Jun 30, 2024 | -9.36% |
| Mar 31, 2024 | -27.21% |
| Dec 31, 2023 | -28.47% |
| Sep 30, 2023 | 52.78% |
| Jun 30, 2023 | 19.42% |
| Mar 31, 2023 | 9.94% |
| Dec 31, 2022 | 3.01% |
| Sep 30, 2022 | 80.76% |
| Jun 30, 2022 | 83.69% |
| Mar 31, 2022 | 94.45% |
| Dec 31, 2021 | 109.04% |
| Sep 30, 2021 | 83.96% |